Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07

Olga Zegarra-Moran, Leila Romio, Chiara Folli, Emanuela Caci, Frederic Becq, Jean Michel Vierfond, Yvette Mettey, Giulio Cabrini, Pascale Fanen, Luis J V Galietta

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

1. This study compares the effect of three chemically unrelated cystic fibrosis transmembrane conductance regulator (CFTR) activators on epithelial cell monolayers expressing the G551D-CFTR mutant. 2. We measured Cl- transport as the amplitude of short-circuit current in response to the membrane permeable cAMP analogue 8-(4-chlorophenylthio)adenosine-3′-5′-cyclic monophosphate (CPT-cAMP) alone or in combination with a CFTR opener. The correction of G551D-CFTR defect was quantified by comparison with maximal activity elicited in cells expressing wild type CFTR. To this end we used Fisher rat thyroid (FRT) cells transfected with wild type or G551D CFTR, and primary cultures of human nasal epithelial cells. 3. In both types of epithelia, cAMP caused activation of Cl - transport that was inhibited by glibenclamide and not by 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid. After normalising for CFTR expression, the response of FRT-G551D epithelia was 1% that of wild type monolayers. 4. Addition of genistein (10-200 μM), but not of 8-cyclopentyl- 1,3-dipropylxanthine (CPX, 1-100 μM) or of the benzo[c]quinolizinium MPB-07 (10-200 μM) to FRT-G551D epithelia pre-treated with cAMP, stimulated a sustained current that at maximal genistein concentration corresponded to 30% of the response of wild type epithelia. 5. The genistein dose-response curve was bell-shaped due to inhibitory activity at the highest concentrations. The dose-dependence in G551D cells was shifted with respect to wild type CFTR so that higher genistein concentrations were required to observe activation and inhibition, respectively. 6. On human nasal epithelia the correction of G551D-CFTR defective conductance obtained with genistein was 20% that of wild type. The impressive effect of genistein suggests that it might correct the Cl - transport defect on G551D patients.

Original languageEnglish
Pages (from-to)504-512
Number of pages9
JournalBritish Journal of Pharmacology
Volume137
Issue number4
DOIs
Publication statusPublished - Oct 2002

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Genistein
Epithelium
Thyroid Gland
Epithelial Cells
6-hydroxy-10-chlorobenzo(c)quinolizinium
Stilbenes
Nasal Mucosa
Glyburide
Nose
Adenosine
Acids
Membranes

Keywords

  • CF-G551D
  • CFTR
  • CFTRopeners
  • CPX
  • Genestein
  • Monolayers
  • MPB-07
  • Nasalepithelia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. / Zegarra-Moran, Olga; Romio, Leila; Folli, Chiara; Caci, Emanuela; Becq, Frederic; Vierfond, Jean Michel; Mettey, Yvette; Cabrini, Giulio; Fanen, Pascale; Galietta, Luis J V.

In: British Journal of Pharmacology, Vol. 137, No. 4, 10.2002, p. 504-512.

Research output: Contribution to journalArticle

Zegarra-Moran, O, Romio, L, Folli, C, Caci, E, Becq, F, Vierfond, JM, Mettey, Y, Cabrini, G, Fanen, P & Galietta, LJV 2002, 'Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07', British Journal of Pharmacology, vol. 137, no. 4, pp. 504-512. https://doi.org/10.1038/sj.bjp.0704882
Zegarra-Moran, Olga ; Romio, Leila ; Folli, Chiara ; Caci, Emanuela ; Becq, Frederic ; Vierfond, Jean Michel ; Mettey, Yvette ; Cabrini, Giulio ; Fanen, Pascale ; Galietta, Luis J V. / Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. In: British Journal of Pharmacology. 2002 ; Vol. 137, No. 4. pp. 504-512.
@article{6f54f0c53802453f9b6aa7cceed4606f,
title = "Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07",
abstract = "1. This study compares the effect of three chemically unrelated cystic fibrosis transmembrane conductance regulator (CFTR) activators on epithelial cell monolayers expressing the G551D-CFTR mutant. 2. We measured Cl- transport as the amplitude of short-circuit current in response to the membrane permeable cAMP analogue 8-(4-chlorophenylthio)adenosine-3′-5′-cyclic monophosphate (CPT-cAMP) alone or in combination with a CFTR opener. The correction of G551D-CFTR defect was quantified by comparison with maximal activity elicited in cells expressing wild type CFTR. To this end we used Fisher rat thyroid (FRT) cells transfected with wild type or G551D CFTR, and primary cultures of human nasal epithelial cells. 3. In both types of epithelia, cAMP caused activation of Cl - transport that was inhibited by glibenclamide and not by 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid. After normalising for CFTR expression, the response of FRT-G551D epithelia was 1{\%} that of wild type monolayers. 4. Addition of genistein (10-200 μM), but not of 8-cyclopentyl- 1,3-dipropylxanthine (CPX, 1-100 μM) or of the benzo[c]quinolizinium MPB-07 (10-200 μM) to FRT-G551D epithelia pre-treated with cAMP, stimulated a sustained current that at maximal genistein concentration corresponded to 30{\%} of the response of wild type epithelia. 5. The genistein dose-response curve was bell-shaped due to inhibitory activity at the highest concentrations. The dose-dependence in G551D cells was shifted with respect to wild type CFTR so that higher genistein concentrations were required to observe activation and inhibition, respectively. 6. On human nasal epithelia the correction of G551D-CFTR defective conductance obtained with genistein was 20{\%} that of wild type. The impressive effect of genistein suggests that it might correct the Cl - transport defect on G551D patients.",
keywords = "CF-G551D, CFTR, CFTRopeners, CPX, Genestein, Monolayers, MPB-07, Nasalepithelia",
author = "Olga Zegarra-Moran and Leila Romio and Chiara Folli and Emanuela Caci and Frederic Becq and Vierfond, {Jean Michel} and Yvette Mettey and Giulio Cabrini and Pascale Fanen and Galietta, {Luis J V}",
year = "2002",
month = "10",
doi = "10.1038/sj.bjp.0704882",
language = "English",
volume = "137",
pages = "504--512",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07

AU - Zegarra-Moran, Olga

AU - Romio, Leila

AU - Folli, Chiara

AU - Caci, Emanuela

AU - Becq, Frederic

AU - Vierfond, Jean Michel

AU - Mettey, Yvette

AU - Cabrini, Giulio

AU - Fanen, Pascale

AU - Galietta, Luis J V

PY - 2002/10

Y1 - 2002/10

N2 - 1. This study compares the effect of three chemically unrelated cystic fibrosis transmembrane conductance regulator (CFTR) activators on epithelial cell monolayers expressing the G551D-CFTR mutant. 2. We measured Cl- transport as the amplitude of short-circuit current in response to the membrane permeable cAMP analogue 8-(4-chlorophenylthio)adenosine-3′-5′-cyclic monophosphate (CPT-cAMP) alone or in combination with a CFTR opener. The correction of G551D-CFTR defect was quantified by comparison with maximal activity elicited in cells expressing wild type CFTR. To this end we used Fisher rat thyroid (FRT) cells transfected with wild type or G551D CFTR, and primary cultures of human nasal epithelial cells. 3. In both types of epithelia, cAMP caused activation of Cl - transport that was inhibited by glibenclamide and not by 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid. After normalising for CFTR expression, the response of FRT-G551D epithelia was 1% that of wild type monolayers. 4. Addition of genistein (10-200 μM), but not of 8-cyclopentyl- 1,3-dipropylxanthine (CPX, 1-100 μM) or of the benzo[c]quinolizinium MPB-07 (10-200 μM) to FRT-G551D epithelia pre-treated with cAMP, stimulated a sustained current that at maximal genistein concentration corresponded to 30% of the response of wild type epithelia. 5. The genistein dose-response curve was bell-shaped due to inhibitory activity at the highest concentrations. The dose-dependence in G551D cells was shifted with respect to wild type CFTR so that higher genistein concentrations were required to observe activation and inhibition, respectively. 6. On human nasal epithelia the correction of G551D-CFTR defective conductance obtained with genistein was 20% that of wild type. The impressive effect of genistein suggests that it might correct the Cl - transport defect on G551D patients.

AB - 1. This study compares the effect of three chemically unrelated cystic fibrosis transmembrane conductance regulator (CFTR) activators on epithelial cell monolayers expressing the G551D-CFTR mutant. 2. We measured Cl- transport as the amplitude of short-circuit current in response to the membrane permeable cAMP analogue 8-(4-chlorophenylthio)adenosine-3′-5′-cyclic monophosphate (CPT-cAMP) alone or in combination with a CFTR opener. The correction of G551D-CFTR defect was quantified by comparison with maximal activity elicited in cells expressing wild type CFTR. To this end we used Fisher rat thyroid (FRT) cells transfected with wild type or G551D CFTR, and primary cultures of human nasal epithelial cells. 3. In both types of epithelia, cAMP caused activation of Cl - transport that was inhibited by glibenclamide and not by 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid. After normalising for CFTR expression, the response of FRT-G551D epithelia was 1% that of wild type monolayers. 4. Addition of genistein (10-200 μM), but not of 8-cyclopentyl- 1,3-dipropylxanthine (CPX, 1-100 μM) or of the benzo[c]quinolizinium MPB-07 (10-200 μM) to FRT-G551D epithelia pre-treated with cAMP, stimulated a sustained current that at maximal genistein concentration corresponded to 30% of the response of wild type epithelia. 5. The genistein dose-response curve was bell-shaped due to inhibitory activity at the highest concentrations. The dose-dependence in G551D cells was shifted with respect to wild type CFTR so that higher genistein concentrations were required to observe activation and inhibition, respectively. 6. On human nasal epithelia the correction of G551D-CFTR defective conductance obtained with genistein was 20% that of wild type. The impressive effect of genistein suggests that it might correct the Cl - transport defect on G551D patients.

KW - CF-G551D

KW - CFTR

KW - CFTRopeners

KW - CPX

KW - Genestein

KW - Monolayers

KW - MPB-07

KW - Nasalepithelia

UR - http://www.scopus.com/inward/record.url?scp=0036797539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036797539&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0704882

DO - 10.1038/sj.bjp.0704882

M3 - Article

C2 - 12359632

AN - SCOPUS:0036797539

VL - 137

SP - 504

EP - 512

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -